<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The authors report two cases of young patients who developed <z:hpo ids='HP_0001217'>clubbing</z:hpo> and <z:e sem="disease" ids="C0178703" disease_type="Disease or Syndrome" abbrv="">hypertrophic osteoarthropathy</z:e> in one case or lung diffusion disorder in the second, after a long-term use of bevacizumab plus chemotherapy in a palliative setting of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>DISCUSSION: We propose that patients on long-term bevacizumab be examined for <z:hpo ids='HP_0001217'>clubbing</z:hpo> and undergo respiratory function tests and that this would be studied prospectively before beginning trials in evaluating this monoclonal antibody given for 2Â years in an adjuvant setting </plain></SENT>
</text></document>